Life Science Instruments & Consumables Market to Reach USD 167.98 Billion by 2033 | Strong 6.7% CAGR | North America Leads with 38% Share | Key Players: Thermo Fisher Scientific, Agilent Technologies, Danaher, Illumina, Bio-Rad, PerkinElmer, Waters, QIAGE

Market Overview

The global life science instruments and consumables market reached US$ 94.78 billion in 2024, up from US$ 89.37 billion in 2023, and is projected to reach US$ 167.98 billion by 2033, growing at a CAGR of 6.7% during the forecast period 2025-2033. The market growth is driven by rapid technological advancements and increasing investments in healthcare, research, and biotechnology. Consumables such as pipette tips, cell culture plates, and centrifuge tubes are integral to daily laboratory operations, supporting breakthroughs in genomics, proteomics, molecular diagnostics, and other life science research areas. Advanced technologies like Next-Generation Sequencing (NGS) and Polymerase Chain Reaction (PCR) are driving significant adoption, particularly in genomics research and molecular diagnostics. Leading instruments, including Thermo Fisher's Ion GeneStudio S5 System and Agilent's SureSelectXT Target Enrichment System, exemplify the high-impact technologies that are advancing precision research and diagnostic applications. Overall, the market is propelled by innovation in instruments, the essential nature of consumables, and supportive regulatory frameworks that encourage adoption of cutting-edge life science technologies.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/life-science-instruments-and-consumables-market?JUli

Recent Developments:

✅ November 2025: Thermo Fisher Scientific launched an upgraded version of its Ion GeneStudio S5 System with enhanced throughput and accuracy, aimed at accelerating genomics research and clinical applications.

✅ September 2025: Agilent Technologies introduced a new generation of SureSelect Target Enrichment kits optimized for ultra‐deep sequencing, improving performance for complex genomic regions in research and diagnostics.

✅ July 2025: Merck KGaA expanded production capacity for high‐performance consumables such as pipette tips and cell culture plastics, supporting increased global demand from academic and industrial research labs.

✅ May 2025: Beckman Coulter Life Sciences unveiled a next‐generation automated centrifuge platform designed to streamline sample processing and boost reproducibility in molecular biology workflows.

✅ March 2025: QIAGEN launched a new PCR instrument series with integrated digital multiplexing capability to support rapid pathogen detection and high‐throughput applications in clinical diagnostics.

✅ Ongoing 2024-2025: Major genomics and proteomics laboratories are adopting AI‐enhanced bioinformatics software bundled with sequencing and analysis instruments to improve data interpretation and accelerate discovery.

Mergers & Acquisitions:

✅ Thermo Fisher Scientific completed the acquisition of a genomics instrumentation specialist in 2025 to broaden its NGS and single‐cell analysis portfolio, enhancing its competitive edge in high‐throughput sequencing and precision research.

✅ Agilent Technologies acquired a bio‐analytical software firm in 2025 to strengthen its integrated data analysis offerings for proteomics and genomics workflows, enabling users to derive deeper insights from instrument outputs.

✅ Merck KGaA finalized its acquisition of a laboratory consumables manufacturer in 2024 to expand its cell culture plastics, filtration solutions, and pipette tips portfolio, boosting capacity and geographic reach.

✅ QIAGEN acquired a PCR reagent and assay development company in 2025, enhancing its molecular diagnostics consumables range and enabling faster pathogen detection kits that are fully compatible with existing PCR platforms.

✅ PerkinElmer merged with a bioprocess instrumentation provider in 2025 to combine complementary technologies in liquid handling, microplate readers, and automated sample prep systems, creating a more cohesive solutions portfolio for life science workflows.

Buy Now & Unlock 360° Market Intelligence:-https://www.datamintelligence.com/buy-now-page?report=life-science-instruments-and-consumables-market?Juli

Key Players:

Thermo Fisher Scientific - Holds a 15.8% share, driven by a broad portfolio of instruments, consumables, and reagents for genomics, proteomics, and molecular diagnostics.

Agilent Technologies - Holds a 12.5% share, supported by advanced analytical instruments and integrated software solutions for life science research.

Danaher - Holds an 11.2% share, fueled by its extensive offerings in diagnostics, bioprocessing, and laboratory automation systems.

Illumina - Holds a 10.7% share, led by next-generation sequencing platforms and genomic analysis consumables.

Bio-Rad - Holds an 8.9% share, driven by PCR instruments, reagents, and life science research consumables.

PerkinElmer - Holds an 8.4% share, supported by analytical instruments, liquid handling solutions, and bioprocess consumables.

Waters - Holds a 7.1% share, specializing in chromatography, mass spectrometry instruments, and related consumables.

QIAGEN - Holds a 6.8% share, driven by molecular diagnostics assays, PCR reagents, and sample prep consumables.

Roche - Holds a 6.2% share, leveraging diagnostic instruments and research reagents across genomics and proteomics applications.

Eppendorf - Holds a 5.4% share, supported by laboratory equipment, pipettes, and cell culture consumables for research and clinical labs.

Market Segmentation:

➥ By Product Type, instruments dominate with a 60% share, driven by high demand for advanced analytical and diagnostic equipment such as PCR machines, NGS platforms, and chromatography systems. Consumables account for 40%, including pipette tips, cell culture plates, reagents, and other lab essentials that support daily research and diagnostics workflows.

➥ By Technology, Polymerase Chain Reaction (PCR) leads with a 22% share, fueled by widespread use in molecular biology, diagnostics, and genomic testing. Next-Generation Sequencing (NGS) holds 18%, driven by the surge in genomic research and precision medicine initiatives. Mass spectrometry accounts for 12%, while chromatography contributes 10%, supporting high-throughput analysis in research and pharma applications. Flow cytometry and microscopy together represent 15%, spectroscopy 8%, electrophoresis 6%, and other emerging technologies make up 9% of the market.

➥ By Application, genomics dominates with a 28% share, driven by increased adoption of NGS and genomic profiling. Proteomics holds 18%, supported by mass spectrometry and protein analysis workflows. Cell biology accounts for 15%, molecular biology 12%, clinical diagnostics 14%, pharmaceuticals 8%, and other applications contribute 5%, reflecting adoption in environmental testing, food safety, and academic research.

➥ By End-User, pharmaceutical & biotechnology companies lead with a 35% share, utilizing instruments and consumables for R&D, drug discovery, and bioprocessing. Academic & research institutes hold 25%, leveraging advanced technologies for fundamental and applied life science research. Hospitals represent 20%, focused on clinical diagnostics and patient testing. Diagnostic laboratories account for 15%, while other end-users such as government labs and contract research organizations (CROs) contribute 5%.

Regional Insights:

North America dominates the global life science instruments and consumables market, holding a 38% share, driven by strong R&D investments, presence of leading life science companies, and advanced healthcare infrastructure. The U.S., in particular, is a key market due to high adoption of next-generation sequencing, PCR, and high-throughput screening technologies. Europe follows with a 28% share, supported by well-established pharmaceutical and biotechnology sectors, increasing government funding for research, and widespread use of advanced laboratory technologies across countries like Germany, the U.K., and France.

The Asia-Pacific region is witnessing rapid growth with a 22% share, fueled by expanding pharmaceutical and biotechnology industries, rising research activities, increasing government initiatives in genomics and diagnostics, and growing healthcare spending in countries such as China, India, and Japan. Latin America and the Middle East & Africa together hold 12% of the market, with growth driven by emerging research institutions, expanding clinical diagnostics infrastructure, and rising adoption of modern laboratory instruments and consumables. Overall, regional growth is largely influenced by technological advancements, R&D investment, and the increasing prevalence of life science research and clinical diagnostics worldwide.

Speak to Our Analyst and Get Customization in the report as per your requirements:-https://www.datamintelligence.com/customize/life-science-instruments-and-consumables-market?Juli

Market Dynamics:

Drivers:
Rising adoption of next-generation sequencing (NGS) in oncology diagnostics is significantly driving the genomics in cancer care market growth. NGS allows comprehensive profiling of hundreds to thousands of genes simultaneously, detecting single nucleotide variants, insertions, deletions, copy number alterations, and gene fusions in a single test. This enables oncologists to identify actionable mutations and design targeted treatment strategies, significantly improving patient outcomes. For instance, in July 2025, Illumina Inc. unveiled the TruSight Oncology 500 v2 assay, delivering comprehensive genomic profiling to support therapy selection and clinical trial matching, with an enhanced sample-to-analysis workflow for research laboratories.

Restraints:
Limited reimbursement policies and regulatory challenges are hampering market growth. Despite advancements, genomic tests such as NGS and comprehensive genomic profiling remain expensive, and standardized reimbursement frameworks are lacking, particularly in emerging markets. While the U.S. Centers for Medicare & Medicaid Services provides coverage for some FDA-approved NGS-based diagnostics, similar support is inconsistent in Europe and Asia-Pacific. Regulatory complexities further hinder innovation and commercialization, restraining the market's growth potential.

Opportunities:
The increasing emphasis on precision medicine and personalized oncology treatments presents significant opportunities. Rising investments in genomic research, growing collaborations between biotech companies and healthcare institutions, and expanding applications of liquid biopsy technologies for early detection and disease monitoring are expected to fuel market expansion. Emerging markets, with improving healthcare infrastructure and rising cancer prevalence, also offer untapped growth potential.

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape

✅ Sustainability Impact Analysis

✅ KOL / Stakeholder Insights

✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots

✅ Market Volatility & Emerging Risks Analysis

✅ Quarterly Industry Report Updated

✅ Live Market & Pricing Trends

✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?Juli

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.